OncoMatch/Clinical Trials/NCT07198867
A Study of A-CAR028 Treatment in Subjects With Relapsed or Refractory Acute Myeloid Leukemia
Is NCT07198867 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies A-CAR028 for acute myeloid leukemia (aml).
Treatment: A-CAR028 — This is a single-center, open-label study to evaluate the safety and efficacy of A-CAR028 in relapsed/refractory acute myeloid leukemia patients
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: CAR-T cell therapy
Previously treated with CAR-T cell products or genetically modified T cell therapies
Cannot have received: autologous or allogeneic hematopoietic stem cell transplantation
Exception: within 3 months prior to signing the ICF
Autologous or allogeneic hematopoietic stem cell transplantation within 3 months prior to signing the ICF
Lab requirements
Blood counts
Kidney function
Liver function
Cardiac function
Severe heart diseases, including but not limited to, myocardial infarction, angioplasty or stent implantation within 12 months prior to signing the ICF, unstable angina pectoris, severe arrhythmia, history of severe non-ischemic cardiomyopathy, heart failure [excluded]
Adequate organ function; Severe heart diseases, including but not limited to, myocardial infarction, angioplasty or stent implantation within 12 months prior to signing the ICF, unstable angina pectoris, severe arrhythmia, history of severe non-ischemic cardiomyopathy, heart failure [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07198867 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior CAR-T cell therapy, autologous or allogeneic hematopoietic stem cell transplantation disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages